Indivior PLC’s (INDV) Buy Rating Reiterated at Numis Securities Ltd

Numis Securities Ltd restated their buy rating on shares of Indivior PLC (LON:INDV) in a report issued on Thursday, May 4th. Numis Securities Ltd currently has a GBX 490 ($6.33) target price on the specialty pharmaceutical company’s stock.

Several other analysts have also weighed in on the company. Royal Bank of Canada lowered Indivior PLC to a sector performer rating and increased their price target for the company from GBX 370 ($4.78) to GBX 390 ($5.03) in a report on Monday, March 13th. Deutsche Bank AG restated a buy rating and set a GBX 395 ($5.10) price target on shares of Indivior PLC in a report on Friday, February 3rd. Stifel Nicolaus restated a buy rating and set a GBX 500 ($6.45) price target on shares of Indivior PLC in a report on Tuesday, April 4th. Jefferies Group LLC reiterated a buy rating and issued a GBX 490 ($6.33) target price on shares of Indivior PLC in a research note on Thursday, May 4th. Finally, Citigroup Inc increased their target price on Indivior PLC from GBX 320 ($4.13) to GBX 340 ($4.39) and gave the stock a neutral rating in a research note on Thursday, March 2nd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of Buy and an average target price of GBX 419.29 ($5.41).

TRADEMARK VIOLATION WARNING: This news story was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at

In other news, insider Lorna Parker purchased 1,231 shares of the company’s stock in a transaction dated Friday, February 24th. The shares were acquired at an average price of GBX 342 ($4.41) per share, with a total value of £4,210.02 ($5,434.39).

Indivior PLC Company Profile

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

12 Month Chart for LON:INDV

Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply